Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
OHE, in collaboration with RAND Europe, University College London (UCL) and University of Manchester (UoM), has been awarded a new research grant from Cancer Research UK…
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
The Trump Administration proposed an International Pricing Index for reimbursing physician-administered Medicare drugs. A conservative thought leader proposed a different basket of ‘market-oriented’ countries. These differ…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
Market-Driven, Value-Based Advanced Commitment (MVAC) is a new mechanism to help re-direct private-sector R&D investments where they’re needed most. We propose to use MVAC to encourage…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
13 May 2019
OHE Lunchtime Seminar with Pedro Pita Barros on ‘Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures’. To be held on 6 June…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
OHE at ISPOR 2019
8 May 2019
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans, 18-22 May.
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases,…